Open-access Primary penile Kaposi’s sarcoma in HIV-seronegative patient: a case report and literature review

INTRODUCTION

Background

Kaposi’s Sarcoma (KS) is a reticuloendothelial system tumor, that may involve the skin, mucosa and viscera (1). It can be considered a malignant vasoformative neoplasia with endothelial proliferation and spindle cell formation on histologic examination. In recent years, there have been several changes in our understanding of KS, including its evolving epidemiology, pathogenesis, new clinical presentations and associations, descriptions of new histologic variants, and the emergence of novel biomarkers with promising targeted therapeutic agents (2). Despite these advances, KS remains the most prevalent malignancy among patients with acquired immune deficiency syndrome (AIDS), being related with drugs or transplant-associated immunosuppression. To our knowledge, this disease has a tight link to Human Herpesvirus 8 (HHV-8) infection, also known as KSHV (Kaposi Sarcoma-associated Herpes Virus). KS can occur in five different epidemiologic-clinical settings: AIDS-related (also known as epidemic), iatrogenic (iatrogenic immunodeficiency, such as that seen in organ transplant recipients), endemic (commonly in sub-Saharan Africa in individuals seronegative for human immunodeficiency virus, HIV), Classic (also known as sporadic KS) and MSM (man who have sex with man) without HIV infection, who are young or middle aged, not immunocompromised (3, 4). The epidemiology suggests that this cancer had an origin independent of HIV, as well as a directed search of DNA led to the discovery of KSHV involvement in the pathogenesis of KS (5). Actually, it is known that a combination of KSHV infection and impaired host immunity might be responsible for KS. However, although AIDSrelated KS and iatrogenic KS are associated with welldefined immunodeficiency, the impaired immune function in classic KS (related to ‘immunosenescence’, as an ageing immune system) and endemic KS (related to chronic infection and malnutrition) is not exactly characterized. In addition, KSHV can cause: I) two lymphoproliferative disorders, represented by the primary effusion lymphoma (PEL) (6) and the multicentric Castleman disease (MCD) (7), II) an inflammatory syndrome called KSHV inflammatory cytokine syndrome.

Whit regard to the clinical presentation, each recognized variant has different manifestations and different visceral involvement. It has been estimated that KS confined to the penis is uncommon and is more often observed in patients with AIDS (8), representing the first manifestation of KS in approximately 2 to 3% of HIV-positive patients. Otherwise, up to 20% of these patients may develop genital lesions in the course of the systemic disease (9, 10). Even more rare primary KS of the penis may be in case of HIV seronegative patients.

The aim of this study is to describe an uncommon clinical presentation of genital KS in HIV-seronegative man and to perform a narrative literature review of the cases described to date.

Epidemiology

KS, first described by Moritz Kaposi in 1,872, is a rare neoplasm that origins from the endovascular cells in a multifocal way-This enigmatic infrequent malignant disease has since received much resonance after the AIDS epidemic in the early 1980s, with an incidence of classic KS ranged from 0.01 per 100.000 personyears for the UK and 0.2 per 100.000 personyears for the USA. However, currently, the incidence of KS is reported to be 200-fold higher in recipients of solidorgan transplants, known as iatrogenic KS form, rather than in the general population (11). The incidence of KSHV in south Africa is very high, reaching >90% in some population, while in Europe prevalence is 20-30%, in Asia and USA is <10% (3). In the Early 1980s with the onset of AIDS emergency, one of the first sign was the rise of KSHV infections. Indeed, a rise of KS incidence of 20.000 time in general population and 300 times in AIDS patients was estimated compared to other immunosuppressed patients (12) with a higher rate for MSM (13). Moreover, with the introduction of combination antiretroviral therapy (cART) the incidence of AIDS related to KSHV decreased considerably (14).

Physiopathology

KSHV is a large double-stranded DNA herpesvirus with a protein covering by an icosahedral capsid, surrounded by tegument and enclosed in a lipid envelope derived in part from the cell membrane. Different glycoproteins in the viral envelope interact with celltypespecific cellular entry receptors such as integrins (including α3β1, αVβ5 and αVβ3), the cystine-glutamate transporter xCT, heparan sulfate and the tyrosine protein kinase receptor EPHA2). KSHV can infect several different cell types, including endothelial cells, B cells, epithelial cells, dendritic cells, monocytes and fibroblasts. Once inside the cell and after uncoating the virus genome enter in the nucleus where enter in lantecy phaseas episome and undergoes sporadic bouts of lytic reactivation (15). Virus can induce latency in human B cells and endothelial cells, as others Herpes virus. During the latent state expresses the latency locus, which includes ORF71 (who encoding viral inhibitory protein vFLIP), ORF72 (encoding vCyclin), ORF73 (encoding latency-associated nuclear protein (LANA)), ORFK12 (encoding the kaposins, which are signalling proteins) and several microRNAs (miRNAs) (16, 17). The latent genes expressed can promote tumorigenesis supporting the survival of the infected cell. Indeed, vFLIP protein activates I kBκ kinase 1 (IKK1) to stimulate the nuclear factor kBκ (NFκB) pathway to increase cell survival, viral miRNAs inhibit apoptosis. Finally, miRNAs also promote endothelial cell reprogramming, and induces the migration and invasion of endothelial cells and vFLIP promotes vascular proliferation. The reactivation from the latency is determined by different stimuli that are not well defined. During this phase, the virus induces, at first the expression of Immediate early (IE) genes than, Delayed early (DE) genes. Similar to the protein products of latency genes, the protein products of lytic genes can contribute to tumorigenesis. The products of those genes (such as vIL6) can induce proinflammatory and angiogenic factors, including vascular endothelial growth factor (VEGF) and plateletderived growth factor (PDGF) (18, 19). In order to survive and to induce cell survival and cell proliferation, KSHV modulate many host cell signaling pathways, including the phosphoinositide 3kinase (PI3K)-AKT-mTOR pathway, the mitogenactivated protein kinase (MAPK) pathway and the NFκB pathway. KSHV encode also genes with the capacity to inhibit host immune respond. K3 and K5 are lytic genes that encode modulator of immune recognition 1 (MIR1) and MIR2 both of which inhibit major histocompatibility complex (MHC) class I antigen presentation to prevent the immune system. KSHV homologues of interferon regulatory factors (IRFs), viral IRFs (vIRFs), are lytic proteins that inhibit type I interferons. KSHV also encodes three CCchemokine ligands (CCLs, formerly known as vMIPs): vCCL1 (encoded by ORFK6), vCCL2 (encoded by ORFK4) and vCCL3 (encoded by ORFK4.1), which can negatively regulate inflammation. Finally, the KSHV K14 gene encodes for a viral OX2 (vOX2), an immunoglobulin superfamily member with homology to the cellular OX2 membrane glycoprotein (OX2, also known as CD200) that binds to the receptor CD200R and suppressed neutrophil activation, decreased CCL2 (also known as MCP1) and IL8 production and inhibited oxidative burst in neutrophils stimulated to undergo phagocytosis.

Clinical presentation

The behavior of the disease varies from a singular lesion localized in the skin, to a fleeting extensive respiratory and gastrointestinal visceral involvement. All variants of KS cutaneous lesions usually present as multiple, pigmented, raised or flat, painless that do not blanch. Classic variant (also known as sporadic KS) is typically confined to lower limbs with few lesions. Visceral and mucosal disease is rare and usually occurs in the gastrointestinal tract. Endemic is a typical manifestation of African children often present with multiple lymph nodes with lymphoedema and a very aggressive natural history of the disease, including visceral disease. AIDS-related is characterized by multiple cutaneous lesions on the limbs, trunk and face. Mucosal lesions, such as oral lesion, are common (identified in 20% of patients) and visceral involvement is seen in 15% of patients. Related with Iatrogenic immunodeficiency, such as in organ transplantation. Often presents as cutaneous KS lesions but both mucosal and, rarely, visceral disease can occur. Finally, in MSM patients the clinical manifestations included lesions that can occur at any skin sites, usually few. Visceral and mucosal disease is rare (3). Regarding visceral involvement, organ lesions are uncommon (in one study, only 15% of 469 patients had visceral lesions upon diagnosis with AIDSrelated KS) (20). Gastrointestinal and pulmonary lesions are more present in AIDSrelated KS. Pulmonary lesions present with dyspnea, dry cough and sometimes hemoptysis, with or without fever, are lifethreatening. These lesions typically appear as a diffuse reticule nodular infiltrate and/or pleural effusion on chest radiography. Gastrointestinal lesions are usually asymptomatic, but may bleed or cause obstruction, and their presence is usually confirmed at endoscopy. However, CT scans, bronchoscopy and endoscopy are not warranted in patients unless they present symptoms indicative of visceral lesions (3). When there is clinical suspicion of KS, a biopsy sample is taken to confirm the diagnosis histologically. Pathologic diagnosis can often be made using conventional hematoxylin and eosin (H&E) and it shows some characteristic features such as, vascular proliferation in the dermis, an increased number of vessels without an endothelial cell lining, the presence of extravasated blood, spindle cells express endothelial markers and are considered to be the KS tumor cell (CD34, LYVE1 and VEGF receptor 3) (3). As concerned the therapy in patients with forms of KS when immunosuppression is potentially reversible, the firstline approach is to bolster the immune system. IFNα and alitretinoin (a retinoid panagonist receptor), are approved for AIDSrelated KS, as KSHV directed therapy (3). Otherwise, regarding the management of genital KS, no specific therapy has been described to date.

CASE DESCRIPTION

A 71-year-old heterosexual, Caucasian man, referred to our department for the presence of penile neoformation appeared from at least 6 months. At the clinical examination, a 0.6mm x 0.6mm x 0.3mm red painless radish nodule hemangioma-like was found on the gland near the frenulum (Figures 1A and 1B). He did not complain penile bother nor there were palpable inguinal lymph nodes. His past medical history reveled only hypertension and hyperuricemia under treatment. The urine analysis and blood laboratory tests showed normal results. The urine culture was negative for Neisseria Gonorrhoeae, Trichomonas Vaginalis, Ureaplasma Urealitycum, Mycoplasma hominis, Mycoplasma Genitalium, Clamydia Trachomatis. The enzyme-linked immunoassorbant assay (ELISA) sierology was negative for Troponema pallidum and HIV 1-2 infections. A complete surgical excisional biopsy of the lesion was performed, with margin control (Figure-2). The histopathological examination showed a dermal tumor constituted by intersecting fascicles of spindle cells, arranged around slit-like vascular spaces admixed with numerous extravasated red blood cells and scattered inflammatory cells. The immunohistochemical staining evidences for HHV-8 both in the stromal cells and in the endothelial ones. In addition, the spindle cells were positively stained for CD31, CD34, and negatively for AE1, AE3, CITO-B, P63, ACTINA A4. These clinical and histopathological findings were compatible with a typical KS variant. Therefore, computed tomography (CT) of the abdomen and chest was scheduled, not showing any visceral involvement. The 3-months follow-up visit demonstrated the complete remission of the pathology without recurrences (Figure-3).

Figures 1 A and B
Red painless radish nodule hemangiomalike on the gland near the frenulum.
Figures 2
Penile biopsy showed a dermal tumor constituted by intersecting fascicles of spindle cells, arranged around slitlike vascular spaces admixed with numerous extravasated red blood cells and scattered inflammatory cells (A). At higher magnification, spindle cells exhibited mild to moderate atypia (B). Neoplastic cells stained positively for CD34 (C) and HHV-8 (D).
Figures 3
Clinical examination revealed the complete remission of the pathology.

DISCUSSION

Literature review

An English-language literature research was conducted, focusing on the cases of penile KS in HIV positive and negative patients (Table-1). Two different authors (GC. and R. DC.) independently searched Medline, Scopus and PubMed databases using a single query in order to identify all the previous reports describing the diagnosis, clinical presentation, histological findings, therapy and recurrence rate of penile KS. The following terms were included: ((penile) OR penis) AND Kaposi’s sarcoma) AND HIV. Finally, considering the period from 1985 to date, a total of 33 KS cases associated with KSHV, with penis as the only manifestation site of the disease, were found in literature. KS usually affects patients between the fifth and eighth decade of life living on the Mediterranean coastal areas where the HHV-8 infection is widespread. In the KS cases found in literature, patient’s average age was 55.7 years (range 2678 years). As showed by epidemiological evidences that highlight the strong link between the disease pathogenesis and HHV-8 infection, most of the patients with penile KS resulted positive for serology HHV-8 research. Equally, the histopathological examination found typical features of KS (Table-2). Since it was described a high HHV-8 sero-prevalence in individuals with high risk sexual activity, including homosexual, a focus on sexual behaviors are mandatory. However, according to our case, only few patients referred to have risk sexual intercourse (2123). As concerned to the immunological status, three patients with isolated penile KS reported an immunosuppression HIV related (23, 24). The lesions described are definitely variable for manifestation, (nodule (23, 2539), papular (22, 34, 4044), ulcerated (27, 39, 45), granulomatous (21), verrucous (46) dimension 0-5mm (24, 3133, 35, 40, 42, 43, 47), >6mm (21, 26, 28, 30, 34, 36, 37, 4042,46), site (gland (2123, 25, 26, 2845, 48), coronal sulcus (22, 26, 29, 37, 40, 44, 45), prepuce (24, 47, 49), penilshaft (27, 46, 48), scrotum (23), frenulum (30)), color (reddish (23, 2527, 29, 32, 34, 36, 40, 44, 45, 49), purplish (23, 29, 30, 33, 39, 41, 42, 43,), bluish (30, 42), skin colored (24), dark brown (48), number (single (2628, 3033, 35, 36, 38, 39, 4143, 45, 47, 49) to multiple (2125, 29, 34, 37, 40, 44, 46, 48,) and symptomatology (asymptomatic, painfull (45)). The most frequently involved site is the glans, sometimes in associations with swelling and lymphatic edema due to massive involvement and the most common manifestation is a nodular reddish or purplish lesion, single or multiple, sometimes ulcerated too. Lesions may also involve the foreskin, the coronal sulcus, or the meatus. In this last case urinary obstructive symptoms may occur. The involvement of the shaft is rare, usually being related to lesions located on the glans or coronal sulcus. Notably, the lesion observed in our patient was a single red radish pedunculated hemangioma-like lesion of the gland next to the frenulum. To our knowledge, this atypical clinical presentation is similar to others described in literature. Indeed, other comparable lesions described in literature varied from a red purple nodule, or radish 5mm papule in diameter of gland to a 1mm nodule next of the meatus. Nevertheless, it remains a rather infrequent manifestation because of its appearance, that could simulate a benign pedunculated lesion of vessels. According to other cases in literature, our case refers to an immunocompetent HIV-seronegative patient. Therefore, similar cases although rare, could not be infrequent. However, the management of patients with KS should include: exams to exclude ongoing infectious diseases, assessment of patient’s immunological status, histological analysis following surgical biopsy and visceral involvement evaluation through CT or ultrasounds, despite it is not necessary in asymptomatic patients, according to others studies (3). In our case, we managed it with complete surgical excision of the lesion, as described by other authors (24, 26, 28, 30, 31, 35, 36, 3840, 43, 44, 47, 49), with a disease recurrence in five cases (24, 30, 31, 36, 39) from a period of about 1-2 years. Other approaches described in literature could include radiotherapy (25, 29, 37, 42), subtotal circumcision associated with biopsy (45), cryotherapy associated with 5% Imiquimod cream (21), excisional biopsy associated with IFNα (32), biopsy with chemotherapy (39), CO2 (48), biopsy with radiotherapy (46). Furthermore, in five cases no therapy was performed (22, 23, 33, 34), two of them for the spontaneous regression of the disease (33, 34). The clinical course of primary penile KS is variable and no standardized follow-up exists to date. In general, local recurrences are rare if the primary tumor is completely removed. In one of them (33) the authors refer recurrence of a new penis lesion after seven months, then after one year two lesions on both legs and one on conjunctiva. Other cases of recurrences occurred for therapy with biopsy with IFNα (32) and with CO2 (48). Respect the management of recurrence, it was described only a recurrence after excisional biopsy (24) in which case it was treated with a new biopsy with radiotherapy, with no recurrence. In our patient, at 6-months from surgery there are no signs of disease progression, although it is a too short follow-up period.

Table 1
Data of patients with Kaposi’s Sarcoma.
Table 2
Treatment, histopathological findings and recurrence of patients with KS.

CONCLUSION

New-onset apparently benign lesions of penis in immunocompetent patients, even in absence of risk factors for sexually transmitted diseases, should be always investigated, because it could represent the first manifestation of primary KS in which penis could be the only isolated clinical presentation. The surgical management could represent a good therapeutic option, leading to disease clinical resolution with no further recurrence, thus providing histological diagnosis.

REFERENCES

  • 1 Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027-38.
  • 2 Pantanowitz L, Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol. 2004;16:443-9.
  • 3 Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:9.
  • 4 Friedman-Kien AE, Saltzman BR, Cao YZ, Nestor MS, Mirabile M, Li JJ, et al. Kaposi’s sarcoma in HIV-negative homosexual men. Lancet. 1990;335:168-9.
  • 5 Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865-9.
  • 6 Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186-91.
  • 7 Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276-80.
  • 8 Marmor M, Friedman-Kien AE, Laubenstein L, Byrum RD, William DC, D’onofrio S, et al. Risk factors for Kaposi’s sarcoma in homosexual men. Lancet. 1982;1:1083-7.
  • 9 Bayne D, Wise GJ. Kaposi sarcoma of penis and genitalia: a disease of our times. Urology. 1988;31:22-5.
  • 10 Lowe FC, Lattimer DG, Metroka CE. Kaposi’s sarcoma of the penis in patients with acquired immunodeficiency syndrome. J Urol. 1989;142:1475-7.
  • 11 Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol. 2015;42:247-57.
  • 12 Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335:123-8.
  • 13 International Agency for Reseach on Cancer. in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 100B (International Agency for Reseach on Cancer, 2012).
  • 14 Roshan R, Labo N, Trivett M, Miley W, Marshall V, Coren L, et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget. 2017;8:109402-16.
  • 15 Bechtel JT, Liang Y, Hvidding J, Ganem D. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol. 2003;77:6474-81.
  • 16 Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72:1005-12.
  • 17 Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi’s sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci U S A. 2005;102:5570-5.
  • 18 Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature. 1997;385:347-50.
  • 19 Cavallin LE, Ma Q, Naipauer J, Gupta S, Kurian M, Locatelli P, et al. KSHV-induced ligand mediated activation of PDGF receptor-alpha drives Kaposi’s sarcomagenesis. PLoS Pathog. 2018;14:e1007175.
  • 20 Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32:409-14.
  • 21 Kuriyama Y, Shimizu A, Yamada K, Yasuda M, Amano H, Tamura A, et al. Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. J Dermatol. 2018;45:e175-e176.
  • 22 De Rose AF, Justich M, Mantica G, Testino N, Terrone C. Kaposi’s sarcoma: An unusual penile lesion in a HIV negative patient. Arch Ital Urol Androl. 2017;89:164-5.
  • 23 Fairley JL, Denham I, Yoganathan S, Read TR. Topical imiquimod 5% as a treatment for localized genital Kaposi’s sarcoma in an HIV-negative man: a case report. Int J STD AIDS. 2012;23:907-8.
  • 24 Kampantais S, Gourvas V, Ioannidis S. Penile Kaposi’s sarcoma in a HIV negative HHV-8 positive man. Hippokratia. 2013;17:96.
  • 25 Lebari D, Gohil J, Patnaik L, Wasef W. Isolated penile Kaposi’s sarcoma in a HIV-positive patient stable on treatment for three years. Int J STD AIDS. 2014;25:607-10.
  • 26 Cecchi R, Troiano M, Ghilardi M, Bartoli L. Kaposi sarcoma of the penis in an HIV-negative patient. J Cutan Med Surg. 2011;15:118-20.
  • 27 Karami H, Bagher-Tabrizi A, Yaghoobi M. Primary Kaposi Sarcoma of Penis in HIV Negative Patient. Iran J Cancer Prev. 2012 Fall;5:225-7.
  • 28 Angulo JC, Lopez JI, Unda-Urzaiz M, Larrinaga JR, Zubiaur CL, Flores NC. Kaposi’s sarcoma of the penis as an initial urological manifestation of AIDS. A report of two cases. Urol Int. 1991;46:235-7.
  • 29 Gonen M, Cenker A, Kiyici H, Kalkan M. Penile Kaposi’s sarcomas in a circumcised and HIV-seronegative patient. Int J Urol. 2006;13:318-20.
  • 30 Kim KH, Choi JI, Ryu KH, Kang IH, Leng YH, Lee JW, et al. Primary Classic Kaposi’s Sarcoma of the Penis in an HIV-Negative Patient. Korean J Urol. 2010;51:803-6.
  • 31 Seleit I, Attia A, Maraee A, Samaka R, Bakry O, Eid E. Isolated Kaposi Sarcoma in two HIV negative patients. J Dermatol Case Rep. 2011;5:24-6.
  • 32 Zargari O. Exclusive penile Kaposi’s sarcoma: report of an HIV-negative man successfully treated with radiotherapy. J Eur Acad Dermatol Venereol. 2006;20:318-20.
  • 33 Guevara JFA, Fernández SL, Claros OR, Villalta PG, Lostal JLC, Abarzuza MAR. Kaposi sarcoma of th e penis in anHIV-negative patient. Einstein (Sao Paulo). 2019;17:eRC4504.
  • 34 Conger K, Sporer A. Kaposi sarcoma limited to glans penis. Urology. 1985;26:173-5.
  • 35 Maiche AG, Holsti P, Grohn P, Wasenius VM. Kaposi’s sarcoma of penis. Br J Urol. 1986;58:557.
  • 36 Marquart KH, Oehlschlaegel G, Engst R. Disseminated Kaposi’s sarcoma that is not associated with acquired immunodeficiency syndrome in a bisexual man. Arch Pathol Lab Med. 1986;110:346-7.
  • 37 Jaimovich L, Calb I, Kaminsky A. Kaposi’s sarcoma of the conjunctiva. J Am Acad Dermatol. 1986;14:589-92.
  • 38 Casado M, Jimenez F, Borbujo J, Almagro M. Spontaneous healing of Kaposi’s angiosarcoma of the penis. J Urol. 1988;139:1313-5.
  • 39 Zambolin T, Simeone C, Baronchelli C, Cunico SC. Kaposi’s sarcoma of the penis. Br J Urol. 1989;63:645-6.
  • 40 Lands RH, Ange D, Hartman DL. Radiation therapy for classic Kaposi’s sarcoma presenting only on the glans penis. J Urol. 1992;147:468-70.
  • 41 Myslovaty B, Kyzer S, Koren R, Chaimoff C. Kaposi sarcoma limited to the glans penis. Plast Reconstr Surg. 1993;92:764.
  • 42 Guy M, Singer D, Barzilai N, Eisenkraft S. Primary classic Kaposi’s sarcoma of glans penis--appearance on magnetic resonance imaging. Br J Urol. 1994;74:521-2.
  • 43 Grunwald MH, Amichai B, Halevy S. Purplish penile papule as a presenting sign of Kaposi’s sarcoma. Br J Urol. 1994;74:517.
  • 44 Ruszczak Z, Stadler R, Schwartz RA. Kaposi’s sarcoma limited to penis treated with cobalt-60 radiotherapy. J Med. 1996;27:211-20.
  • 45 Koyuncuolu M, Yalçin N, Ozkan S, Kirkali Z. Primary Kaposi’s sarcoma of the glans penis. Br J Urol. 1996;77:614-5.
  • 46 Berkmen F, Celebiolu AS. Adult genitourinary sarcomas: a report of seventeen cases and review of the literature. J Exp Clin Cancer Res. 1997;16:45-8.
  • 47 Chun YS, Chang SN, Park WH. A case of classical Kaposi’s sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol. 1999;26:240-3.
  • 48 Schwartz RA, Cohen JB, Watson RA, Gascón P, Ahkami RN, Ruszczak Z, et al. Penile Kaposi’s sarcoma preceded by chronic penile lymphoedema. Br J Dermatol. 2000;142:153-6.
  • 49 Kavak A, Akman RY, Alper M, Büyükbabani N. Penile Kaposi’s sarcoma in a human immunodeficiency virus-seronegative patient. Br J Dermatol. 2001;144:207-8.

Publication Dates

  • Publication in this collection
    31 July 2020
  • Date of issue
    Sep-Oct 2020

History

  • Received
    02 July 2019
  • Accepted
    06 Oct 2019
  • Published
    30 Nov 2019
location_on
Sociedade Brasileira de Urologia Rua Bambina, 153, 22251-050 Rio de Janeiro RJ Brazil, Tel. +55 21 2539-6787, Fax: +55 21 2246-4088 - Rio de Janeiro - RJ - Brazil
E-mail: brazjurol@brazjurol.com.br
rss_feed Stay informed of issues for this journal through your RSS reader
Acessibilidade / Reportar erro